Board & BedsideCLINICAL KNOWLEDGE FOR THE REAL WORLD

FNP Pharmacology Practice Questions for the Boards, With a Timed Quiz

Title card: FNP Pharmacology Practice Questions, 15 board style questions with full rationales and a 15 minute timed quiz. Board & Bedside

By Daniel Borkert, FNP-C
Last reviewed October 23, 2026. Checked against the sources named below on October 23, 2026.

Most pharmacology studying fails in a predictable way. Students drill drug names on flashcards until the names feel familiar, then sit for an exam that almost never asks what a drug is called. The boards ask what a prescriber does. A patient on lisinopril is coughing. A kidney result has slipped on a drug that was safe last year. A new antibiotic has quietly doubled the effect of a blood thinner. Every question below is one of those moments, taken from the Board & Bedside question bank and set in the outpatient clinic, where FNP prescribing actually happens.

Each question comes with its answer, the mechanism underneath the answer, and a note on why each wrong option fails. That last part is where the learning is. A rationale that only defends the right answer teaches one fact. A rationale that dismantles the wrong answers teaches the pattern the next question will wear.

In this guide

The short answer

This page holds 15 board-style pharmacology questions with full rationales, covering the prescribing decisions FNP candidates are actually tested on. Renin-angiotensin drugs and their monitoring, statins, heart failure therapy, anticoagulation and its interactions, diabetes and thyroid drugs, an antidepressant safety case, and outpatient antibiotics and their interactions. Every question is an outpatient primary care scenario. Read them straight through with the answers showing, or take them timed, 15 questions in 15 minutes, at the pace the boards run. The set is calibrated to be hard, on purpose, and a score on it is a readiness signal from one small timed set. It is not a predictor of passing, and this page will not pretend otherwise.

If you want the facts organized before you test them, the companion cheat sheet lays out every class on this page in tables.

Why these fifteen

The bank these questions were drawn from holds hundreds of questions in total, and the rule for choosing this set was simple. Each question had to turn on a decision a prescriber makes, not a fact a student recites. Knowing what to monitor after starting a drug, not just naming the drug. Recognizing the toxicity, not just listing it. Removing the drug that caused the problem instead of the drug that is protecting the patient. Three of the fifteen end by sending the patient in for emergency evaluation, and that is deliberate too. Knowing which drug harms cannot be managed from the clinic is a pharmacology skill, and the boards test it.

In my own practice, the classes I most often see prescribed badly are the antipsychotics and the antidepressants, along with the medications on the Beers criteria list that older adults are taking, such as NSAIDs.

Want the sheet that goes with this quiz? Join the free student list. Your printable FNP pharmacology cheat sheet will be emailed to you, plus a short sequence of study emails over the following two weeks.

Read them, or take them timed

Two ways, and they teach different things.

Read mode is the default below. Each question is followed by its answer and rationale, so the set works as a study session. Read the stem, commit to an answer before you look, then read all four rationale lines, including the ones for the options you never considered.

Timed mode layers a clock on the same questions, 15 minutes for the set, answers held until the end, the way the boards feel.

Take the timed pharmacology quiz

The timed quiz needs JavaScript. If it does not load, the full set is in read mode below. The questions are never held hostage to the tool.

Whichever mode you choose, the score language on this page stays honest. Fifteen questions cannot sort pass from fail. They can show you which class is soft, and that is what the score is for.

Blood pressure and cholesterol

Question 1

A 58-year-old woman started on lisinopril 10 mg daily for hypertension develops a persistent dry cough after 3 weeks. She has no fever, wheezing, or URI symptoms. What is the most appropriate next step?

  • A. Switch lisinopril to losartan
  • B. Switch lisinopril to benazepril
  • C. Continue lisinopril and add dextromethorphan for the cough
  • D. Continue lisinopril and reassure her the cough will resolve on its own

Answer: A

ACE inhibitor-induced dry cough (from bradykinin accumulation) is managed by switching to an ARB, which blocks the angiotensin receptor without inhibiting bradykinin breakdown and rarely causes cough.

Why the other options fail:

  • B. Benazepril is another ACE inhibitor and shares the bradykinin mechanism, so the cough would be expected to recur. The fix is to leave the class for an ARB, not to switch within it.
  • C. Cough suppressants do not address the bradykinin-mediated mechanism and the cough will persist.
  • D. ACE inhibitor cough typically persists as long as the drug is continued and warrants a switch, not reassurance.

Test taking note. ACEi cough → ARB is a classic one-step question. Note the nuance: after ACE-inhibitor-induced angioedema, ARBs are used only with caution (many clinicians avoid them), but cough alone is never a reason to avoid an ARB.

Question 2

A 64-year-old man with hypertension and no CKD is started on lisinopril. His baseline labs are unremarkable. What laboratory monitoring is most important 2 to 4 weeks after initiation?

  • A. Liver function tests (aminotransferases and bilirubin)
  • B. Urine albumin-to-creatinine ratio (urine albumin excretion)
  • C. Complete blood count (hemoglobin and platelet count)
  • D. Basic metabolic panel (creatinine and potassium)

Answer: D

ACE inhibitors can raise potassium and creatinine by reducing aldosterone and intraglomerular pressure. Guidelines recommend checking a BMP within 2 to 4 weeks of initiation or dose escalation; a creatinine rise up to 30% above baseline is generally acceptable.

Why the other options fail:

  • A. LFTs are not routine monitoring for an ACE inhibitor; the labs that matter here are creatinine and potassium.
  • B. Albuminuria tracking matters in hypertension care, but it does not catch the early creatinine and potassium shifts of the first weeks on an ACE inhibitor, which is the safety question here.
  • C. CBC is not affected by ACE inhibitor initiation.

Test taking note. Any question about starting an ACEi or ARB: the answer is almost always 'check BMP for K+ and creatinine.' The 30% creatinine rise threshold is bonus points.

Question 3

A 57-year-old man with a baseline LDL-C of 148 mg/dL is started on atorvastatin 40 mg daily for primary prevention. According to the 2026 ACC/AHA dyslipidemia guideline, when should his lipid panel be rechecked to assess response and adherence?

  • A. 1 week after the first dose
  • B. 6 months after the first dose
  • C. 12 months after the first dose
  • D. 4 to 12 weeks after the first dose

Answer: D

The 2026 ACC/AHA dyslipidemia guideline recommends a lipid panel 4 to 12 weeks after statin initiation or dose adjustment to assess response and adherence, and every 6 to 12 months thereafter. The panel does not need to be fasting in most patients.

Why the other options fail:

  • A. One week is too early to assess the full LDL-lowering effect.
  • B. Six months is the rhythm for later checks on stable therapy. Waiting that long for the first recheck leaves nonresponse and nonadherence undetected.
  • C. A full year misses the window to detect nonresponse or nonadherence early, and delays any adjustment the first panel would have prompted.

Test taking note. Statin monitoring interval: 4 to 12 weeks after a change, then every 6 to 12 months. This is a pure memorization question, bank the interval.

Heart failure

Question 4

A 64-year-old man with HFrEF takes lisinopril 20 mg daily. His clinician plans to switch him to sacubitril-valsartan. According to the 2022 AHA/ACC/HFSA heart failure guideline, what precaution is required?

  • A. Start sacubitril-valsartan the same day as the last lisinopril dose
  • B. Overlap both drugs for one week to avoid rebound
  • C. Hold the ACE inhibitor for 36 hours before the first ARNI dose
  • D. Start sacubitril-valsartan 12 hours after the last lisinopril dose

Answer: C

A 36-hour washout after the last ACE inhibitor dose is required before starting sacubitril-valsartan because combined ACE and neprilysin inhibition markedly increases angioedema risk. (No washout is needed when switching from an ARB.)

Why the other options fail:

  • A. Same-day initiation without washout risks life-threatening angioedema.
  • B. Overlapping ACE inhibitor and ARNI therapy is contraindicated.
  • D. Twelve hours is still inside the washout window. The full 36 hours must pass after the last ACE inhibitor dose, whatever the dose timing.

Test taking note. ACEi → ARNI = 36-hour washout (angioedema). ARB → ARNI = no washout. Boards love testing which switch needs the washout.

Question 5

A 73-year-old woman with HFrEF takes digoxin 0.125 mg daily. She develops nausea, visual changes, and new confusion. Her potassium is 2.9 mEq/L. What is the most likely explanation and appropriate action?

  • A. Emergent head CT to evaluate for stroke before changing any therapy
  • B. Hold digoxin and arrange immediate emergency evaluation
  • C. Attribute the symptoms to a viral illness and continue all medications
  • D. Increase the digoxin dose to compensate for the low potassium

Answer: B

Nausea, visual disturbances, and confusion are classic digoxin toxicity, and hypokalemia increases myocardial sensitivity to digoxin even at therapeutic levels. Hold digoxin and arrange immediate emergency evaluation with ECG, renal function, and electrolyte monitoring; outpatient electrolyte correction and a drug level alone are not sufficient with new confusion and visual symptoms.

Why the other options fail:

  • A. Confusion does warrant urgent evaluation, but imaging alone misses the cause in front of you. The symptom cluster plus hypokalemia in a patient taking digoxin is toxicity until proven otherwise.
  • C. Visual changes and confusion do not fit a simple viral illness, and hypokalemia in a patient on digoxin must be addressed.
  • D. These are toxicity symptoms, made more likely by the low potassium. Raising the dose would deepen the toxicity.

Test taking note. Digoxin toxicity triggers: hypokalemia, hypomagnesemia, renal dysfunction. Symptoms: nausea, vision changes (yellow-green halos), confusion, arrhythmias.

Anticoagulation

Question 6

A 78-year-old man with atrial fibrillation takes warfarin 5 mg daily with previously stable INRs between 2.0 and 3.0. He was started on trimethoprim-sulfamethoxazole 4 days ago for a urinary tract infection. Today's INR is 4.8. He reports no bleeding, bruising, or falls. What is the most appropriate next step?

  • A. Hold warfarin, resume at a reduced dose once the INR returns to range, and recheck the INR in 2 to 5 days
  • B. Continue warfarin at the current dose of 5 mg daily, with no bleeding reported, and recheck the INR in 1 month
  • C. Stop warfarin permanently, start aspirin 81 mg daily alone for stroke prevention, and discontinue INR monitoring
  • D. Give oral vitamin K today, recheck the INR in 24 hours, and continue warfarin at the current dose

Answer: A

Trimethoprim-sulfamethoxazole inhibits CYP2C9, the enzyme that clears warfarin, raising the INR. The effect is fast, with prothrombin time rises documented between the second and sixth day of combined therapy. A supratherapeutic INR without bleeding is managed by holding one or more doses, resuming at a lower dose, and rechecking the INR in 2 to 5 days. Counsel on consistent vitamin K intake and checking for interactions before starting any new drug or antibiotic.

Why the other options fail:

  • B. Continuing unchanged risks further INR rise and bleeding; a 1-month recheck is too infrequent during an active drug interaction.
  • C. Aspirin alone is inadequate stroke prophylaxis for atrial fibrillation, and stopping anticoagulation without a replacement plan is unsafe.
  • D. Vitamin K is not recommended for an asymptomatic INR in this range. It overshoots, complicates re-anticoagulation, and is reserved for bleeding or urgent reversal. Continuing the same dose also ignores the interaction still in effect.

Test taking note. Supratherapeutic INR without bleeding: hold, reduce, recheck. Vitamin K is for bleeding or urgent reversal, not for an asymptomatic number.

Question 7

A 70-year-old woman with atrial fibrillation takes apixaban 5 mg twice daily. She started taking ibuprofen 400 mg daily for knee arthritis 2 weeks ago and now reports gum bleeding when brushing her teeth. Her blood pressure and labs are stable. What is the most appropriate counseling and management?

  • A. Hold apixaban for 3 days until the gum bleeding stops, and continue the ibuprofen for pain
  • B. Stop apixaban, switch to aspirin 81 mg daily for stroke prevention, and recheck her in 2 weeks
  • C. Stop the ibuprofen, switch to acetaminophen for pain, and continue apixaban while the bleeding stays minor and stable
  • D. Continue ibuprofen at the same dose, add a proton pump inhibitor for gastric protection, and continue apixaban

Answer: C

NSAIDs increase bleeding risk in patients on anticoagulants through platelet inhibition and mucosal injury, compounding the effect of apixaban. Stop the NSAID, substitute acetaminophen, and assess bleeding severity and stability; continue apixaban for minor self-limited bleeding, and arrange urgent evaluation for significant or persistent bleeding. Stopping anticoagulation in atrial fibrillation without cause exposes her to stroke risk.

Why the other options fail:

  • A. Holding apixaban leaves her atrial fibrillation unprotected for days and does nothing about the drug that caused the bleeding. The precipitant is the ibuprofen, and it is the thing to remove.
  • B. Aspirin is weaker stroke prophylaxis for atrial fibrillation and carries its own bleeding risk. It swaps one problem for two.
  • D. A proton pump inhibitor only protects against gastric mucosal injury and does nothing for systemic bleeding risk from combined NSAID-anticoagulant use; the NSAID must be stopped.

Test taking note. Any bleeding on a DOAC: first look for the added bleeder, NSAIDs, alcohol, new supplements. Remove the precipitant before touching the anticoagulant; stopping the DOAC is rarely the right first move.

Diabetes and thyroid

Question 8

A 71-year-old man with type 2 diabetes takes metformin 1000 mg twice daily. His eGFR has declined from 52 to 38 mL/min/1.73m2. He has no acute illness. What is the most appropriate medication safety assessment?

  • A. Continue metformin at the current dose of 1000 mg twice daily with no change in monitoring
  • B. Stop metformin immediately; it is contraindicated below an eGFR of 60
  • C. Continue the current dose and recheck the eGFR in one year
  • D. Reduce metformin to a maximum of 1000 mg daily and monitor renal function closely

Answer: D

Metformin is contraindicated at eGFR <30 and should not be initiated at eGFR 30-45. When eGFR falls into the 30-45 range during therapy, FDA labeling directs a benefit-risk assessment; standard clinical practice is to reduce to a maximum of 1000 mg daily with close renal monitoring, due to lactic acidosis risk.

Why the other options fail:

  • A. Metformin accumulates as renal function declines; continuing full dose at eGFR 38 increases lactic acidosis risk.
  • B. The contraindication threshold is eGFR <30, not 60; stopping outright at 38 forfeits a useful agent unnecessarily.
  • C. A year is far too long to leave full dose metformin unmonitored at an eGFR of 38. The dose reduction and closer follow-up happen now.

Test taking note. Metformin renal rules: stop <30, don't start 30-45, max 1000 mg/day if already on it in the 30-45 range.

Question 9

A 68-year-old woman with type 2 diabetes and heart failure with reduced ejection fraction (EF 35%) has an A1C of 8.3% on metformin. Which medication addition is most appropriate?

  • A. Add a sulfonylurea
  • B. Add a DPP-4 inhibitor
  • C. Add pioglitazone
  • D. Add an SGLT2 inhibitor

Answer: D

SGLT2 inhibitors (dapagliflozin, empagliflozin) reduce heart failure hospitalization and cardiovascular death in patients with HFrEF with or without diabetes, and ADA Standards of Care recommend them for type 2 diabetes with heart failure independent of A1C.

Why the other options fail:

  • A. Sulfonylureas offer no heart failure benefit and add hypoglycemia risk.
  • B. DPP-4 inhibitors are weight- and hypo-neutral but have no demonstrated heart failure outcome benefit (saxagliptin even increased HF hospitalization).
  • C. Pioglitazone causes fluid retention, is not recommended in symptomatic heart failure, and starting it in NYHA class III or IV heart failure is contraindicated.

Test taking note. T2DM + heart failure = SGLT2 inhibitor (dapagliflozin/empagliflozin). Pioglitazone is not recommended in symptomatic heart failure, and starting it in NYHA class III or IV is contraindicated.

Question 10

A 52-year-old asymptomatic woman has TSH 7.8 mIU/L with a normal free T4 on two occasions. She is not pregnant and takes no interfering medications. What is the most appropriate next step?

  • A. Start levothyroxine 50 mcg daily now; treatment is recommended once the TSH passes 7 mIU/L
  • B. Reassure her and repeat thyroid testing only if symptoms develop
  • C. Start methimazole 10 mg daily to lower the TSH
  • D. Check anti-TPO antibodies and recheck the TSH in 2 to 3 months, deferring treatment for now

Answer: D

This is subclinical hypothyroidism (elevated TSH, normal free T4). Treatment should be considered when TSH exceeds 10 mIU/L. Below 10, the decision is individualized: symptoms, age, pregnancy plans, goiter, cardiovascular context, antibody status, and patient preference all inform it. Positive TPO antibodies predict progression to overt hypothyroidism but alone do not uniformly mandate treatment. Monitoring with repeat TSH and antibody assessment is appropriate when treatment is deferred.

Why the other options fail:

  • A. The threshold at which treatment should be considered is a TSH above 10 mIU/L, not 7. At 7.8 in an asymptomatic patient, monitoring is the supported path.
  • B. Subclinical hypothyroidism can progress to overt disease, so follow-up is scheduled on a calendar, not left waiting for symptoms.
  • C. Methimazole treats hyperthyroidism and is contraindicated in hypothyroidism.

Test taking note. Subclinical hypo: consider treatment at TSH >10; below that, an individualized decision (pregnancy, symptoms, goiter, CV risk, antibodies, patient preference). TPO positivity alone does not mandate treatment. Otherwise watch.

Question 11

A 38-year-old woman taking methimazole 20 mg daily for Graves disease for 6 weeks develops fever of 101.8F and a severe sore throat. What is the most appropriate action?

  • A. Reassure her; fever is a common and benign effect of methimazole
  • B. Stop methimazole immediately and obtain an urgent CBC
  • C. Reduce the methimazole dose by half
  • D. Add an antibiotic and continue methimazole

Answer: B

Fever and sore throat in a patient on methimazole can signal agranulocytosis (absolute neutrophil count <500), a rare but life-threatening adverse effect. The drug must be stopped immediately with urgent CBC; if confirmed, it must never be restarted and alternative definitive therapy (radioiodine or surgery) is needed.

Why the other options fail:

  • A. These symptoms cannot be assumed benign in this context; they are agranulocytosis until a CBC proves otherwise, and missing it can be fatal.
  • C. Dose reduction does not mitigate agranulocytosis risk once suspected; the drug must be stopped.
  • D. Antibiotics do not address the underlying neutrophil failure, and continuing the drug is dangerous.

Test taking note. Methimazole + fever/sore throat = agranulocytosis until proven otherwise: STOP drug, urgent CBC.

Mood

Question 12

A 72-year-old woman has taken sertraline 100 mg daily for 3 months with good mood improvement. Her daughter reports new confusion and unsteadiness over the past week. Labs: Na+ 128 mEq/L (baseline 140), K+ 4.1, creatinine 0.9. She is euvolemic with no diuretic use. What is the best next step?

  • A. Hold sertraline and arrange urgent hospital evaluation for symptomatic hyponatremia
  • B. Start donepezil for new-onset dementia
  • C. Increase sertraline to 150 mg daily for residual symptoms
  • D. Reassure the family that a sodium of 128 requires no action in an older adult

Answer: A

SSRIs can cause SIADH with hyponatremia, most often in older adults and within the first weeks to months of therapy. New confusion with Na+ 128 mEq/L is clinically significant. Management is to confirm with a BMP and osmolality, hold the offending SSRI, correct sodium cautiously, and switch to a non-SSRI antidepressant (e.g., bupropion or mirtazapine) if ongoing treatment is needed. Confusion with Na+ 128 mEq/L is symptomatic hyponatremia requiring urgent hospital evaluation with monitored correction, not outpatient management.

Why the other options fail:

  • B. Acute confusion with documented hyponatremia is a metabolic cause, not dementia; treating it as dementia misses a reversible emergency.
  • C. Increasing the SSRI will worsen SIADH-mediated hyponatremia.
  • D. Na+ 128 with confusion is not benign and requires evaluation and correction.

Test taking note. Elderly + SSRI + new confusion/fall = check sodium; SSRIs cause SIADH. Treat the metabolic cause before labeling it dementia.

Infection and inflammation

Question 13

A 26-year-old woman with no drug allergies has a positive rapid antigen test for group A Streptococcus. She is otherwise healthy. What is the most appropriate treatment?

  • A. Amoxicillin 500 mg twice daily for 10 days
  • B. Azithromycin 500 mg on day 1, then 250 mg daily for 4 days
  • C. Amoxicillin-clavulanate 875/125 mg twice daily for 10 days
  • D. Ibuprofen alone, since most pharyngitis resolves without antibiotics

Answer: A

Penicillin and amoxicillin remain the first-line treatments for confirmed group A streptococcal pharyngitis per IDSA guidance, Streptococcus pyogenes has never developed penicillin resistance. A 10-day course eradicates the organism and prevents acute rheumatic fever. Amoxicillin is preferred for its once- or twice-daily dosing and palatability.

Why the other options fail:

  • B. Macrolides are reserved for patients with true penicillin allergy; they are not first-line, and rising macrolide resistance makes empiric azithromycin a poor default choice.
  • C. Amoxicillin-clavulanate adds unnecessary broad-spectrum coverage (and more gastrointestinal side effects) for an organism fully susceptible to plain amoxicillin.
  • D. Most pharyngitis is viral and needs no antibiotic, but a positive rapid antigen test confirms group A streptococcus, where antibiotics are required to prevent rheumatic fever. Supportive care alone is inadequate.

Test taking note. Positive rapid strep in a non-allergic patient = penicillin or amoxicillin, full 10 days. Save azithromycin for true penicillin allergy, it is never the first-line pick.

Question 14

A 68-year-old man has a first episode of non-severe Clostridioides difficile infection with 5 watery stools per day. Labs: WBC 11,200, creatinine at baseline, no hypotension or megacolon. His insurance does not cover fidaxomicin, which he cannot afford out of pocket. What is the most practical first-line treatment?

  • A. Oral vancomycin 125 mg twice daily for 10 days
  • B. Metronidazole 500 mg three times daily for 10 days
  • C. Oral vancomycin 125 mg four times daily for 10 days
  • D. Loperamide as needed, with oral hydration and no antibiotic

Answer: C

The 2021 IDSA guideline prefers fidaxomicin for an initial episode because of lower recurrence rates, but its cost puts it out of reach for this patient. Oral vancomycin 125 mg four times daily for 10 days is the practical first-line therapy. Metronidazole is no longer recommended as first-line for any episode.

Why the other options fail:

  • A. The drug is right but the regimen is not. Oral vancomycin treats C. difficile from inside the gut lumen and is dosed four times daily; twice daily dosing underdoses the infection.
  • B. Metronidazole was the old first line, but its cure rates run lower than vancomycin's, and current IDSA guidance reaches for it only for a non-severe first episode when vancomycin and fidaxomicin cannot be used. Here oral vancomycin is available, so the outdated default is the wrong pick.
  • D. Supportive care alone leaves the infection untreated, and antimotility agents such as loperamide are discouraged in acute C. difficile infection because they may precipitate toxic megacolon.

Test taking note. C. diff first episode: fidaxomicin is guideline-preferred, but oral vancomycin 125 mg four times daily is the practical first-line because of cost. Metronidazole is out.

Question 15

A 68-year-old man with gout (eGFR 38 mL/min) takes colchicine 0.6 mg twice daily. Three days after starting clarithromycin for pneumonia, he develops severe watery diarrhea, diffuse myalgias, and weakness. Labs show new leukopenia. What is the most likely explanation?

  • A. An acute gout flare; increase the colchicine dose until the flare fully resolves
  • B. Clarithromycin-induced QT prolongation leading to arrhythmia
  • C. Colchicine toxicity from drug interaction and renal impairment
  • D. Allopurinol hypersensitivity syndrome with rash and organ injury

Answer: C

Clarithromycin inhibits CYP3A4 and P-glycoprotein, markedly raising colchicine levels, especially dangerous with eGFR 38, and its early toxicity signs are gastrointestinal distress (severe diarrhea), myalgias, and cytopenias. Stop colchicine immediately and arrange urgent emergency evaluation; avoid clarithromycin-colchicine coadministration in renal impairment.

Why the other options fail:

  • A. More colchicine would worsen toxicity; the diarrhea-plus-myalgia pattern signals overdose, not undertreatment.
  • B. QT prolongation presents with syncope or arrhythmia, not severe diarrhea and myalgias.
  • D. Allopurinol hypersensitivity causes rash, eosinophilia, and organ injury, not this GI-muscular toxicity pattern, and he is not taking allopurinol.

Test taking note. When a new symptom cluster follows a newly added drug, work the interaction first: identify the metabolic pathway (CYP3A4/P-gp here) and the organ that clears the original drug (kidney here).

What this set is really testing

Spread all fifteen out and the same four questions keep surfacing underneath them. What is the mechanism? The cough, the toxicity, and the interaction are all mechanisms wearing patient clothes. Which patients are at risk? The kidney patient on metformin, the older adult on the SSRI, the gout patient handed the wrong antibiotic partner. What monitoring does it need? The metabolic panel after the ACE inhibitor, the INR after the interacting antibiotic, the CBC the week a methimazole patient spikes a fever. And what does it interact with? Colchicine with clarithromycin, ibuprofen with apixaban, an antibiotic with warfarin.

A candidate who studies pharmacology as those four questions stops memorizing drugs one at a time. The classes organize themselves, and a question about a drug never seen before can still be answered, because the class behavior is known.

The board fact that mattered at the bedside in my practice is this one. Amlodipine can cause swelling.

Study the set like a prescriber

When a question goes wrong, name the failure before you move on. A mechanism miss means the class table needs another pass. A monitoring miss means the lab schedule was never learned as part of the drug. A disposition miss, managing in clinic what belonged in the emergency department, is the most expensive kind, on the exam and after it. Keeping a wrong-answer log, writing each miss and its pattern down, is what turns fifteen questions into a study plan.

My rule of thumb, the one I reach for every week, is this. Start low and go slow.

The rest of the bank

These fifteen are the free sample of a larger set. The full bank holds 650 board style questions written to the same standard, outpatient scenarios, mechanism rationales, and a note on every wrong option, organized by system so a soft area can be drilled on its own.

Frequently asked questions

Are these questions harder than the boards?

They are calibrated to be hard, and the page says so rather than dressing them up as typical. The bank was written to the shape of the real exam, outpatient scenarios that turn on a prescribing decision, so working these questions at speed is practice in the form the real questions take, even where the content is new. Hard and honest beats easy and flattering, because the exam does not grade on encouragement.

What does my timed quiz score say about my readiness?

Less than you want it to. Fifteen questions can flag a weak class, a slow pace, or a habit of changing right answers, and all three are worth knowing. They cannot estimate a pass probability, and any tool that converts a set this size into a readiness verdict is selling false precision.

Is this a predictor exam?

No. A predictor is a full length, blueprint weighted instrument with outcome data behind its cut scores, and this is a 15 question study set with a timer. It is built for learning and for an honest look at pace, nothing more.

Why do some answers send the patient to the emergency department from a primary care question?

Because that is the correct pharmacology answer for digoxin toxicity with confusion, for symptomatic hyponatremia on an SSRI, and for colchicine toxicity. Recognizing the limit of the clinic is part of prescribing safely, and the boards reward it.

Sources for this page

Questions drawn from the Board & Bedside question bank and refined for this page, with the original bank text, bank identifiers, and the claim by claim sourcing for every rationale kept in this page's production file. Clinical facts checked against American Family Physician topic reviews and guideline summaries, including its reviews of ACE inhibitor adverse effects, digoxin toxicity, hypothyroidism, and sodium disorders, and its summaries of the KDIGO diabetes in CKD guidance, the 2021 IDSA Clostridioides difficile update, and the group A streptococcal pharyngitis guideline. Guideline sources carried in the questions include the 2026 ACC/AHA dyslipidemia guideline, the 2022 AHA/ACC/HFSA heart failure guideline, and the ADA Standards of Care. FDA prescribing information on DailyMed was used for the labeled thresholds on sacubitril-valsartan, metformin, trimethoprim-sulfamethoxazole, and colchicine. Full claim by claim sourcing is kept with this page's production file and checked at every refresh.

For clinician education only — not medical advice.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *